Can a new antibody tame ENPP1? a safety trial begins
NCT ID NCT07762001
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether a new antibody called AD-NP1 is safe to give to people. The antibody targets a protein called ENPP1, which may play a role in certain diseases. Healthy volunteers will receive either the antibody or a placebo (salt water) as a single intravenous dose, with doses increasing in steps to find the highest dose that is well tolerated. The study will monitor side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AD-NP1, a humanized monoclonal antibody targeting ENPP1, given as a single intravenous dose
- What this could lead to
- If safe, this could pave the way for future studies of AD-NP1 as a potential treatment for diseases involving ENPP1.
- What could go wrong
- This is an early-phase trial focused on safety, not effectiveness. The antibody may cause side effects or fail to show benefit in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOSE ESCALATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA Clinical and Translational Research Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.